were estimated 688 yen per person in selective vaccination strategy compared with 350 yen per person in universal vaccination strategy, with annual discount rate of 3%. On-one way sensitivity analysis, estimated costs were sensitive to annual discount rates and risks of HBV infections. Absolute difference in the HBV management costs was relatively small compared with vaccine program costs. Since the management of HBV reactivation was not always provided for all patients at risk, a further cost analysis should be conducted by reflecting real-world clinical practice. Results:
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